Using a chatbot to improve genetic risk assessment for hereditary cancer
Official title: Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population
Run by Weill Medical College of Cornell University · NCT05562778 · Data updated 2026-11-12
This study is testing if a chatbot can help more patients at risk for hereditary cancer get recommended for genetic testing compared to regular care in a gynecology clinic.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 4 sites (Brooklyn, New York and 3 other locations) |
| Status | Recruiting |
| Started | January 15, 2023 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT05562778 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 8 years and older who are scheduled for a new patient appointment in a gynecology clinic and have not previously undergone genetic testing.
✕Probably not a fit
Patients who have already had genetic testing for hereditary cancer syndromes or are under 18 years of age will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares a mobile health platform, specifically a chatbot utilizing artificial intelligence and natural language processing, to standard care in a gynecology clinic. The goal is to determine if the chatbot can enhance the recommendation rates for genetic testing among patients at higher risk for hereditary cancer syndromes. Additionally, the study will assess barriers to access and utilization of genetic testing services among these patients. Participants must be 8 years or older, scheduled for a new patient appointment, and have not undergone prior genetic testing.
Why it matters
Potential benefit: If successful, this approach could significantly increase the identification of patients who would benefit from genetic testing for hereditary cancer syndromes.
How similar studies have gone: While the use of chatbots in healthcare is emerging, this specific application for hereditary cancer risk assessment is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 8 years of age or older. * Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English. * Access to a telephone with texting capacity. * Has not had prior genetic testing for hereditary cancer syndromes. Exclusion Criteria: * Under 18 years of age * Has had previous genetic testing for hereditary cancer syndromes * Does not read/speak in English * Does not have access to a phone with texting capabilities
Where it's running
-
NYP Brooklyn Methodist Hospital
Brooklyn, New York, United States Recruiting -
NYP Lower Manhattan Hospital
New York, New York, United States Recruiting -
Weill Cornell Medicine
New York, New York, United States Recruiting -
NYP Medical Group Queens
Queens, New York, United States Recruiting
Study contacts
- Principal investigator: Melissa K Frey, MD — Weill Medical College of Cornell University
- Study coordinator: Melissa K Frey, MD, MS
- Email: mkf2002@med.cornell.edu
- Phone: 212-746-3049
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NMTCuff vs standard TOF monitoring during gynecologic oncology surgery
This study tests whether NMTCuff monitoring can better detect neuromuscular recovery than standard TOF monitoring in women undergoing laparoscopic gynecologic cancer surgery.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
-
Personalized supervised exercise program for adults with breast or gynecologic cancer
A small pilot study will test a supervised, personalized exercise program to see if it is safe, feasible, and acceptable for adults with a history of breast or gynecologic cancer.
-
Cesium-131 brachytherapy to preserve organs in recurrent cervical or endometrial cancer
This study tests whether implanting small cesium-131 seeds can provide targeted radiation to vaginal recurrences of cervical or endometrial cancer in patients who previously had pelvic radiation, with the goal of preserving organs.
-
National registry of endometrial cancer cases in Italy
This project will collect clinical and molecular information from adults treated for endometrial cancer at participating Italian oncology centers to see if a national database can improve understanding of outcomes and care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.